OncoMatch/Clinical Trials/NCT06879379
KPD Consolidation After ASCT in NDMM Patients
Is NCT06879379 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies KPD (carfilzomib, pomalidomide, and dexamethasone) consolidation for multiple myeloma, newly diagnosed.
Treatment: KPD (carfilzomib, pomalidomide, and dexamethasone) consolidation — This study aims to evaluate the efficacy and safety of post-transplant consolidation therapy with the KPD regimen (carfilzomib, pomalidomide, and dexamethasone) versus no consolidation, followed by maintenance therapy, in patients with transplant-eligible newly diagnosed multiple myeloma (TE-NDMM). The primary goal is to compare minimal residual disease (MRD) negativity rates and overall treatment outcomes between the two groups.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: triplet or quadraplet induction regimen — upfront
Received upfront triplet or quadraplet induction regimen
Must have received: autologous stem cell transplant — upfront
Received upfront ASCT after induction
Lab requirements
Liver function
ALT/AST ≤ 2.5 × UNL; serum total bilirubin ≤ 1.5 × UNL (if congenitally high bilirubin, direct bilirubin ≤ 1.5 × UNL)
Cardiac function
LVEF ≥ 50% as diagnosed by echocardiography, with no clinically significant ECG abnormalities
Adequate Organ Function Reserve: ALT/AST ≤ 2.5 × UNL; serum total bilirubin ≤ 1.5 × UNL (if congenitally high bilirubin, direct bilirubin ≤ 1.5 × UNL); LVEF ≥ 50% as diagnosed by echocardiography, with no clinically significant ECG abnormalities; basal oxygen saturation > 95% in room air
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify